JPH0433798B2 - - Google Patents
Info
- Publication number
- JPH0433798B2 JPH0433798B2 JP61093514A JP9351486A JPH0433798B2 JP H0433798 B2 JPH0433798 B2 JP H0433798B2 JP 61093514 A JP61093514 A JP 61093514A JP 9351486 A JP9351486 A JP 9351486A JP H0433798 B2 JPH0433798 B2 JP H0433798B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- formula
- general formula
- compound
- ethylene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 150000001875 compounds Chemical class 0.000 claims abstract description 44
- -1 methylene, ethylene, propylene, ethylidene, methoxyethylene, benzyloxyethylene Chemical group 0.000 claims abstract description 14
- 238000000034 method Methods 0.000 claims abstract description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 7
- UAYCAARGGQRWMQ-UHFFFAOYSA-N 1-ethenoxy-1-ethoxyethane Chemical group CCOC(C)OC=C UAYCAARGGQRWMQ-UHFFFAOYSA-N 0.000 claims abstract description 4
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims abstract description 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 49
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 14
- 239000002609 medium Substances 0.000 claims description 10
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 9
- 239000012312 sodium hydride Substances 0.000 claims description 9
- 229910000104 sodium hydride Inorganic materials 0.000 claims description 9
- 239000000741 silica gel Substances 0.000 claims description 8
- 229910002027 silica gel Inorganic materials 0.000 claims description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 6
- 229910021529 ammonia Inorganic materials 0.000 claims description 6
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 6
- 238000004587 chromatography analysis Methods 0.000 claims description 6
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims description 5
- 239000003456 ion exchange resin Substances 0.000 claims description 5
- 229920003303 ion-exchange polymer Polymers 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- 239000012736 aqueous medium Substances 0.000 claims description 4
- AZDCYKCDXXPQIK-UHFFFAOYSA-N ethenoxymethylbenzene Chemical group C=COCC1=CC=CC=C1 AZDCYKCDXXPQIK-UHFFFAOYSA-N 0.000 claims description 4
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 4
- CSRZQMIRAZTJOY-UHFFFAOYSA-N trimethylsilyl iodide Chemical compound C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 claims description 4
- LVOASXNJWPROPP-UHFFFAOYSA-N (4-methylphenyl)sulfonyloxymethylphosphonic acid Chemical compound CC1=CC=C(S(=O)(=O)OCP(O)(O)=O)C=C1 LVOASXNJWPROPP-UHFFFAOYSA-N 0.000 claims description 3
- 229910052783 alkali metal Inorganic materials 0.000 claims description 3
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 3
- 125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 claims description 3
- XJRBAMWJDBPFIM-UHFFFAOYSA-N methyl vinyl ether Chemical group COC=C XJRBAMWJDBPFIM-UHFFFAOYSA-N 0.000 claims description 3
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 3
- 230000001476 alcoholic effect Effects 0.000 claims description 2
- 150000001340 alkali metals Chemical class 0.000 claims description 2
- 125000006295 amino methylene group Chemical group [H]N(*)C([H])([H])* 0.000 claims description 2
- 239000000010 aprotic solvent Substances 0.000 claims description 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 abstract description 25
- 238000002360 preparation method Methods 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 4
- 125000000217 alkyl group Chemical group 0.000 abstract description 2
- 230000000840 anti-viral effect Effects 0.000 abstract description 2
- 230000004071 biological effect Effects 0.000 abstract description 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 229930024421 Adenine Natural products 0.000 description 22
- 229960000643 adenine Drugs 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical group CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 229910003002 lithium salt Inorganic materials 0.000 description 9
- 159000000002 lithium salts Chemical class 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 8
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 235000011114 ammonium hydroxide Nutrition 0.000 description 3
- WGQMNJYLZXTHIN-UHFFFAOYSA-N dimethoxyphosphorylmethyl 4-methylbenzenesulfonate Chemical compound COP(=O)(OC)COS(=O)(=O)C1=CC=C(C)C=C1 WGQMNJYLZXTHIN-UHFFFAOYSA-N 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- SUPKOOSCJHTBAH-UHFFFAOYSA-N adefovir Chemical compound NC1=NC=NC2=C1N=CN2CCOCP(O)(O)=O SUPKOOSCJHTBAH-UHFFFAOYSA-N 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 239000003957 anion exchange resin Substances 0.000 description 2
- 125000003435 aroyl group Chemical group 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 239000003729 cation exchange resin Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 238000011033 desalting Methods 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- DLYUQMMRRRQYAE-UHFFFAOYSA-N tetraphosphorus decaoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 2
- 150000000180 1,2-diols Chemical class 0.000 description 1
- OHVLMTFVQDZYHP-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CN1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O OHVLMTFVQDZYHP-UHFFFAOYSA-N 0.000 description 1
- HWCLMKDWXUGDKL-UHFFFAOYSA-N 1-ethenoxy-2-ethoxyethane Chemical group CCOCCOC=C HWCLMKDWXUGDKL-UHFFFAOYSA-N 0.000 description 1
- BYUNYALHUMSCSA-UHFFFAOYSA-N 2-ethenoxyoxane Chemical group C=COC1CCCCO1 BYUNYALHUMSCSA-UHFFFAOYSA-N 0.000 description 1
- BKLZHVCAEBYXHN-UHFFFAOYSA-N 3-(6-aminopurin-9-yl)propoxymethylphosphonic acid Chemical compound NC1=NC=NC2=C1N=CN2CCCOCP(O)(O)=O BKLZHVCAEBYXHN-UHFFFAOYSA-N 0.000 description 1
- FCZOVUJWOBSMSS-UHFFFAOYSA-N 5-[(6-aminopurin-9-yl)methyl]-5-methyl-3-methylideneoxolan-2-one Chemical compound C1=NC2=C(N)N=CN=C2N1CC1(C)CC(=C)C(=O)O1 FCZOVUJWOBSMSS-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 1
- TYBWABJIIOVYOR-UHFFFAOYSA-N OCC(C(O)=O)OP(=O)=O Chemical class OCC(C(O)=O)OP(=O)=O TYBWABJIIOVYOR-UHFFFAOYSA-N 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
- 229910001863 barium hydroxide Inorganic materials 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 229940023913 cation exchange resins Drugs 0.000 description 1
- FZXSSJIKXCFPDP-UHFFFAOYSA-N chloro(dichlorophosphoryl)methane Chemical compound ClCP(Cl)(Cl)=O FZXSSJIKXCFPDP-UHFFFAOYSA-N 0.000 description 1
- MOFCYHDQWIZKMY-UHFFFAOYSA-N chloromethylphosphonic acid Chemical compound OP(O)(=O)CCl MOFCYHDQWIZKMY-UHFFFAOYSA-N 0.000 description 1
- 238000010549 co-Evaporation Methods 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000002242 deionisation method Methods 0.000 description 1
- UOEFFQWLRUBDME-UHFFFAOYSA-N diethoxyphosphorylmethyl 4-methylbenzenesulfonate Chemical compound CCOP(=O)(OCC)COS(=O)(=O)C1=CC=C(C)C=C1 UOEFFQWLRUBDME-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- AFQIYTIJXGTIEY-UHFFFAOYSA-N hydrogen carbonate;triethylazanium Chemical compound OC(O)=O.CCN(CC)CC AFQIYTIJXGTIEY-UHFFFAOYSA-N 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- GTTBQSNGUYHPNK-UHFFFAOYSA-N hydroxymethylphosphonic acid Chemical class OCP(O)(O)=O GTTBQSNGUYHPNK-UHFFFAOYSA-N 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000000654 isopropylidene group Chemical class C(C)(C)=* 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 125000004170 methylsulfonyl group Chemical class [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- DTMFTBZNVFUECB-UHFFFAOYSA-N n-[9-(2-hydroxyethyl)purin-6-yl]benzamide Chemical compound N1=CN=C2N(CCO)C=NC2=C1NC(=O)C1=CC=CC=C1 DTMFTBZNVFUECB-UHFFFAOYSA-N 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N phosphonic acid group Chemical group P(O)(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 125000005499 phosphonyl group Chemical group 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000004187 tetrahydropyran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 125000002088 tosyl group Chemical class [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CS853017A CS263951B1 (en) | 1985-04-25 | 1985-04-25 | 9-(phosponylmethoxyalkyl)adenines and method of their preparation |
| CS3017-85 | 1985-04-25 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS61275289A JPS61275289A (ja) | 1986-12-05 |
| JPH0433798B2 true JPH0433798B2 (OSRAM) | 1992-06-04 |
Family
ID=5369028
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP61093514A Granted JPS61275289A (ja) | 1985-04-25 | 1986-04-24 | ９−（ホスホニルメトキシアルキル）アデニン，その製造法及びその利用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US4808716A (OSRAM) |
| EP (1) | EP0206459B1 (OSRAM) |
| JP (1) | JPS61275289A (OSRAM) |
| AT (1) | ATE78259T1 (OSRAM) |
| AU (1) | AU580151B2 (OSRAM) |
| CA (1) | CA1295614C (OSRAM) |
| CS (1) | CS263951B1 (OSRAM) |
| DE (1) | DE3686002T2 (OSRAM) |
| DK (1) | DK173625B1 (OSRAM) |
| EG (1) | EG18079A (OSRAM) |
| HK (1) | HK213296A (OSRAM) |
| NO (1) | NO174510B (OSRAM) |
| NZ (1) | NZ215925A (OSRAM) |
Families Citing this family (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5047533A (en) * | 1983-05-24 | 1991-09-10 | Sri International | Acyclic purine phosphonate nucleotide analogs |
| US4845084A (en) * | 1984-01-26 | 1989-07-04 | Merck & Co., Inc. | Phosphate derivatives of substituted butyl guanines, antiviral compositions containing them, and methods of treating viral infections with them |
| CS264222B1 (en) * | 1986-07-18 | 1989-06-13 | Holy Antonin | N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them |
| IL84477A (en) * | 1986-11-18 | 1995-12-08 | Bristol Myers Squibb Co | History of Phosphonomethoxyalkylene Purinopyrimidine and Pharmaceutical Preparations Containing Them |
| US5650510A (en) * | 1986-11-18 | 1997-07-22 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Antiviral phosphonomethoxyalkylene purine and pyrimidine derivatives |
| IL88518A (en) * | 1987-11-30 | 1994-02-27 | Beecham Group Plc | 3-(phosphoryl methoxyethoxy) -purine derivatives, their preparation and pharmaceutical compositions containing them |
| US5247085A (en) * | 1987-11-30 | 1993-09-21 | Beecham Group P.L.C. | Antiviral purine compounds |
| EP0335770B1 (en) * | 1988-04-01 | 1997-01-15 | Merrell Pharmaceuticals Inc. | Novel fluorophosphonate nucleotide derivatives |
| EP0339161A1 (en) * | 1988-04-01 | 1989-11-02 | Merrell Dow Pharmaceuticals Inc. | Novel fluorophosphonate nucleotide derivatives |
| US5284837A (en) * | 1988-05-06 | 1994-02-08 | Medivir Ab | Derivatives of purine, process for their preparation and a pharmaceutical preparation |
| EP0353955A3 (en) * | 1988-08-02 | 1991-08-14 | Beecham Group Plc | Novel compounds |
| US5744600A (en) * | 1988-11-14 | 1998-04-28 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Phosphonomethoxy carbocyclic nucleosides and nucleotides |
| US4966895A (en) * | 1989-02-02 | 1990-10-30 | Merck & Co. Inc. | Cyclic monophosphates of purine and pyrimidine acyclonucleosides as anti-retroviral agents |
| US5688778A (en) * | 1989-05-15 | 1997-11-18 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Nucleoside analogs |
| GB8912043D0 (en) * | 1989-05-25 | 1989-07-12 | Beecham Group Plc | Novel compounds |
| US5302585A (en) * | 1990-04-20 | 1994-04-12 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Use of chiral 2-(phosphonomethoxy)propyl guanines as antiviral agents |
| CS387190A3 (en) * | 1990-08-06 | 1992-03-18 | Ustav Organicke Chemie A Bioch | (2r)-2-/di(2-propyl)phosphonylmethoxy/-3-p-toluenesulfonyloxy -1- trimethylacetoxypropane and process for preparing thereof |
| CA2088363C (en) * | 1990-08-10 | 2002-05-28 | Purushotham Vemishetti | Process for the preparation of nucleotides |
| ATE167679T1 (de) * | 1990-09-14 | 1998-07-15 | Acad Of Science Czech Republic | Wirkstoffvorläufer von phosphonaten |
| US5208221A (en) * | 1990-11-29 | 1993-05-04 | Bristol-Myers Squibb Company | Antiviral (phosphonomethoxy) methoxy purine/pyrimidine derivatives |
| US6057305A (en) | 1992-08-05 | 2000-05-02 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Antiretroviral enantiomeric nucleotide analogs |
| US5514798A (en) * | 1993-06-02 | 1996-05-07 | Gilead Sciences, Inc. | Method and cyclic carbonates for nucleotide analogues |
| US5656745A (en) * | 1993-09-17 | 1997-08-12 | Gilead Sciences, Inc. | Nucleotide analogs |
| AU690587B2 (en) * | 1993-09-17 | 1998-04-30 | Gilead Sciences, Inc. | Method for dosing therapeutic compounds |
| US5798340A (en) | 1993-09-17 | 1998-08-25 | Gilead Sciences, Inc. | Nucleotide analogs |
| DE4408534A1 (de) * | 1994-03-14 | 1995-09-28 | Hoechst Ag | Substituierte N-Ethyl-Glycinderivate zur Herstellung von PNA und PNA-/DNA-Hybriden |
| US6465650B1 (en) | 1995-03-13 | 2002-10-15 | Aventis Pharma Deutschland Gmbh | Substituted N-ethylglycine derivatives for preparing PNA and PNA/DNA hybrids |
| US5977061A (en) * | 1995-04-21 | 1999-11-02 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | N6 - substituted nucleotide analagues and their use |
| US5877166A (en) * | 1996-04-29 | 1999-03-02 | Sri International | Enantiomerically pure 2-aminopurine phosphonate nucleotide analogs as antiviral agents |
| US5733788A (en) * | 1996-07-26 | 1998-03-31 | Gilead Sciences, Inc. | PMPA preparation |
| ES2198003T3 (es) * | 1996-07-26 | 2004-01-16 | Gilead Sciences, Inc. | Analogos de nucleotidos. |
| BR9811045A (pt) * | 1997-07-25 | 2000-08-22 | Gilead Sciences Inc | Composição de análogo de nucleotìdeo e processo de sìntese |
| US5935946A (en) * | 1997-07-25 | 1999-08-10 | Gilead Sciences, Inc. | Nucleotide analog composition and synthesis method |
| AU2645199A (en) * | 1998-11-18 | 2000-06-05 | Viktor Veniaminovich Tets | Dialkyl-1-aryl-1-(2,4-dioxo-5-amino-1,3-pyrimidin-5-yl)methy lphosphonates |
| US7205404B1 (en) * | 1999-03-05 | 2007-04-17 | Metabasis Therapeutics, Inc. | Phosphorus-containing prodrugs |
| CZ304886B6 (cs) | 2000-07-21 | 2015-01-07 | Gilead Sciences, Inc. | Prekurzory léčiv na bázi fosfonátových analogů nukleotidů a způsoby jejich výběru a přípravy |
| EA006020B1 (ru) * | 2001-06-29 | 2005-08-25 | Инститьют Оф Оргэник Кемистри Энд Байокемистри Оф Зе Экэдеми Оф Сайэнс Оф Зе Чек Рипаблик | Производные 6-[2-(фосфонометокси)алкокси]пиримидинов, обладающие антивирусной активностью, способ их получения (варианты) и способ лечения вирусной инфекции |
| US7388002B2 (en) | 2001-11-14 | 2008-06-17 | Biocryst Pharmaceuticals, Inc. | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases |
| PL374525A1 (en) * | 2001-11-14 | 2005-10-31 | Biocryst Pharmaceuticals, Inc. | Nucleosides preparation thereof and use as inhibitors of rna viral polymerases |
| WO2004037161A2 (en) * | 2002-05-13 | 2004-05-06 | Metabasis Therapeutics, Inc. | Cyclic prodrugs of pmea one of its analogues |
| JP4332496B2 (ja) * | 2002-05-13 | 2009-09-16 | メタバシス・セラピューティクス・インコーポレイテッド | Ｐｍｅａおよびｐｍｐａ環生成合成 |
| US7417036B2 (en) * | 2002-11-12 | 2008-08-26 | Tianjin Kinsly Pharmaceutical Co. Ltd. | Crystal form of adefovir dipivoxil and its preparation |
| AP2089A (en) | 2003-01-14 | 2010-01-11 | Gilead Sciences Inc | Compositions and methods for combination antiviraltherapy |
| CA2527805C (en) | 2003-06-16 | 2012-08-21 | Institute Of Organic Chemistry And Biochemistry, Academy Of Sciences Of The Czech Republic | Pyrimidine compounds having phosphonate groups as antiviral nucleotide analogs |
| EP1656387A2 (en) * | 2003-07-30 | 2006-05-17 | Gilead Sciences, Inc. | Nucleobase phosphonate analogs for antiviral treatment |
| CA2565966A1 (en) * | 2004-06-08 | 2005-12-29 | Metabasis Therapeutics, Inc. | Lewis acid mediated synthesis of cyclic esters |
| CN100338080C (zh) * | 2004-06-16 | 2007-09-19 | 山东中科泰斗化学有限公司 | 9－[2－(膦羧基甲氧基)乙基]腺嘌呤双环醇酯及其制备方法 |
| UA93354C2 (ru) | 2004-07-09 | 2011-02-10 | Гилиад Сайенсиз, Инк. | Местный противовирусный препарат |
| EP1831235B1 (en) | 2004-12-16 | 2013-02-20 | The Regents of The University of California | Lung-targeted drugs |
| WO2006130217A2 (en) * | 2005-04-01 | 2006-12-07 | The Regents Of The University Of California | Substituted phosphate esters of nucleoside phosphonates |
| TWI471145B (zh) | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
| TWI375560B (en) | 2005-06-13 | 2012-11-01 | Gilead Sciences Inc | Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same |
| KR101294467B1 (ko) | 2005-07-25 | 2013-09-09 | 인터뮨, 인크. | Ｃ형 간염 바이러스 복제의 신규 거대고리형 억제제 |
| WO2007013085A1 (en) * | 2005-07-26 | 2007-02-01 | Hetero Drugs Limited | Novel process for acyclic phosphonate nucleotide analogs |
| DE602006019323D1 (de) * | 2005-10-11 | 2011-02-10 | Intermune Inc | Verbindungen und verfahren zur inhibierung der replikation des hepatitis-c-virus |
| KR20080091767A (ko) * | 2005-12-14 | 2008-10-14 | 씨아이피엘에이 엘티디. | (테노포비어 및 라미뷰딘과 같은) 뉴클레오티드 역전사효소억제제 및 뉴클레오시드 역전사효소 억제제를 투여 단위의상이한 부분에 포함하는 약제학적 조합물 |
| FR2908133B1 (fr) * | 2006-11-08 | 2012-12-14 | Centre Nat Rech Scient | Nouveaux analogues de nucleotides comme molecules precurseurs d'antiviraux |
| DK2159224T3 (da) | 2007-06-18 | 2012-08-20 | Sunshine Lake Pharma Co Ltd | Bromphenylsubstituerede thiazolyldihydropyrimidiner |
| TWI444384B (zh) | 2008-02-20 | 2014-07-11 | Gilead Sciences Inc | 核苷酸類似物及其在治療惡性腫瘤上的用途 |
| US20110059921A1 (en) * | 2008-03-27 | 2011-03-10 | Ektar Therapeutics | Oligomer-Nitrogenous Base Conjugates |
| US7935817B2 (en) * | 2008-03-31 | 2011-05-03 | Apotex Pharmachem Inc. | Salt form and cocrystals of adefovir dipivoxil and processes for preparation thereof |
| BRPI0911260A2 (pt) * | 2008-04-15 | 2015-09-29 | Intermune Inc | composto, composição farmacêutica, método de inibição de atividade da protease de ns3/ns4 in, vitro e usos de compostos |
| US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
| TW201010692A (en) | 2008-06-19 | 2010-03-16 | Public Univ Corp Nagoya City Univ | Pharmaceutical composition for treatment or prevention of hbv infection |
| JP2012505897A (ja) * | 2008-10-15 | 2012-03-08 | インターミューン・インコーポレーテッド | 治療用抗ウイルス性ペプチド |
| CA2748057C (en) | 2008-12-23 | 2018-07-03 | Pharmasset, Inc. | Nucleoside phosphoramidates |
| BRPI0922508A8 (pt) | 2008-12-23 | 2016-01-19 | Pharmasset Inc | Análogos de nucleosídeo |
| EA019295B1 (ru) | 2008-12-23 | 2014-02-28 | Джилид Фармассет, Ллс. | Соединения пуриновых нуклеозидов и способ их получения |
| KR20100108297A (ko) | 2009-03-26 | 2010-10-06 | 주식회사 대웅제약 | 신규 결정형의 아데포비어 디피복실 및 그의 제조방법 |
| EA201290128A1 (ru) * | 2009-09-28 | 2013-01-30 | Интермьюн, Инк. | Новые макроциклические ингибиторы репликации вируса гепатита с |
| TW201116540A (en) * | 2009-10-01 | 2011-05-16 | Intermune Inc | Therapeutic antiviral peptides |
| TWI498117B (zh) | 2010-03-31 | 2015-09-01 | Gilead Pharmasset Llc | 核苷氨基磷酸酯 |
| CN104203275A (zh) | 2010-06-09 | 2014-12-10 | 疫苗技术股份有限公司 | 用于增强抗逆转录病毒治疗的hiv感染者的治疗性免疫 |
| ES2551738T3 (es) | 2010-06-11 | 2015-11-23 | Gilead Sciences, Inc. | Formulaciones tópicas antivirales para la prevención de la transmisión del VHS-2 |
| RU2606845C2 (ru) | 2010-12-10 | 2017-01-10 | СИГМАФАРМ ЛЭБОРЭТОРИЗ, ЭлЭлСи | Высокостабильные композиции перорально активных аналогов нуклеотидов или перорально активных пролекарств аналогов нуклеотидов |
| WO2012154698A2 (en) * | 2011-05-06 | 2012-11-15 | Mckenna Charles E | Method to improve antiviral activity of nucleotide analogue drugs |
| CN107312039B (zh) | 2012-08-30 | 2019-06-25 | 江苏豪森药业集团有限公司 | 一种替诺福韦前药的制备方法 |
| CA2889903C (en) | 2012-10-29 | 2021-03-09 | Manjinder Singh Phull | Antiviral phosphonate analogues and process for preparation thereof |
| CN107056838A (zh) | 2013-03-15 | 2017-08-18 | 加利福尼亚大学董事会 | 无环核苷膦酸二酯 |
| WO2015123352A1 (en) | 2014-02-13 | 2015-08-20 | Ligand Pharmaceuticals, Inc. | Prodrug compounds and their uses |
| US10167302B2 (en) * | 2014-05-23 | 2019-01-01 | University College Cork | Phosphonate nucleosides useful in the treatment of viral diseases |
| CN106687118A (zh) | 2014-07-02 | 2017-05-17 | 配体药物公司 | 前药化合物及其用途 |
| KR102589658B1 (ko) | 2014-09-15 | 2023-10-13 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 뉴클레오타이드 유사체 |
| WO2017048956A1 (en) | 2015-09-15 | 2017-03-23 | The Regents Of The University Of California | Nucleotide analogs |
| EP3372227A1 (en) | 2017-03-06 | 2018-09-12 | MH10 Spolka z ograniczona odpowiedzialnoscia | Tablet formulation of adefovir dipivoxil |
| RU2020126177A (ru) | 2018-01-09 | 2022-02-10 | Лиганд Фармасьютикалз, Инк. | Ацетальные соединения и их терапевтическое применение |
| IL318465A (en) | 2022-07-21 | 2025-03-01 | Antiva Biosciences Inc | Compositions and dosage forms for the treatment of HPV infection and HPV-induced neoplasia |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1523865A (en) * | 1974-09-02 | 1978-09-06 | Wellcome Found | Purine compunds and salts thereof |
| US4347360A (en) * | 1980-09-16 | 1982-08-31 | Ens Bio Logicals Inc. | Ring open nucleoside analogues |
| CS233665B1 (en) * | 1983-01-06 | 1985-03-14 | Antonin Holy | Processing of isomere o-phosphonylmethylderivative of anantiomere racemic vicinal diene |
| GB2150570B (en) * | 1983-05-24 | 1987-04-08 | Stanford Res Inst Int | Novel antiviral agents |
| AU8092587A (en) * | 1986-11-18 | 1988-05-19 | Bristol-Myers Squibb Company | Synthesis of purin-9-ylalkylenoxymethyl phosphonic acids |
-
1985
- 1985-04-25 CS CS853017A patent/CS263951B1/cs not_active IP Right Cessation
-
1986
- 1986-04-11 DK DK198601678A patent/DK173625B1/da not_active IP Right Cessation
- 1986-04-16 EP EP86302822A patent/EP0206459B1/en not_active Expired - Lifetime
- 1986-04-16 DE DE8686302822T patent/DE3686002T2/de not_active Expired - Lifetime
- 1986-04-16 AT AT86302822T patent/ATE78259T1/de not_active IP Right Cessation
- 1986-04-17 AU AU56328/86A patent/AU580151B2/en not_active Expired
- 1986-04-23 NZ NZ215925A patent/NZ215925A/xx unknown
- 1986-04-24 JP JP61093514A patent/JPS61275289A/ja active Granted
- 1986-04-24 NO NO861621A patent/NO174510B/no unknown
- 1986-04-24 CA CA000507444A patent/CA1295614C/en not_active Expired - Lifetime
- 1986-04-25 US US06/856,299 patent/US4808716A/en not_active Expired - Lifetime
- 1986-04-27 EG EG243/86A patent/EG18079A/xx active
-
1996
- 1996-12-05 HK HK213296A patent/HK213296A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DE3686002T2 (de) | 1992-12-17 |
| NO174510B (no) | 1994-02-07 |
| DE3686002D1 (de) | 1992-08-20 |
| EP0206459B1 (en) | 1992-07-15 |
| US4808716A (en) | 1989-02-28 |
| CA1295614C (en) | 1992-02-11 |
| NO861621L (no) | 1986-10-27 |
| NZ215925A (en) | 1989-01-27 |
| EP0206459A3 (en) | 1987-05-20 |
| AU5632886A (en) | 1986-10-30 |
| DK167886A (da) | 1986-10-26 |
| JPS61275289A (ja) | 1986-12-05 |
| EP0206459A2 (en) | 1986-12-30 |
| DK173625B1 (da) | 2001-05-07 |
| CS263951B1 (en) | 1989-05-12 |
| NO174510C (OSRAM) | 1994-05-18 |
| DK167886D0 (da) | 1986-04-11 |
| EG18079A (en) | 1992-06-30 |
| ATE78259T1 (de) | 1992-08-15 |
| HK213296A (en) | 1996-12-06 |
| AU580151B2 (en) | 1989-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH0433798B2 (OSRAM) | ||
| JPH0822866B2 (ja) | プリンおよびピリミジン塩基のｎ−ホスホニルメトキシアルキル誘導体 | |
| Tseng et al. | Synthesis of 3-deazaneplanocin A, a powerful inhibitor of S-adenosylhomocysteine hydrolase with potent and selective in vitro and in vivo antiviral activities | |
| JPH0480914B2 (OSRAM) | ||
| EP0454427B1 (en) | Antiretroviral bases | |
| Yu et al. | Synthesis and antiviral activity of methyl derivatives of 9-[2-(phosphonomethoxy) ethyl] guanine | |
| EP0138656B1 (en) | Cyclic pyrophosphates of purine and pyrimidine acyclonucleosides, their preparation and their application in anti-viral compositions | |
| Parikh et al. | Analogs of Nucleotides. II. Phosphonate Esters of Ribose and Glucopyranosyl Purine Derivatives1 | |
| US4590269A (en) | Process for preparing the cyclic phosphate ester of substituted 9-(1,3-dihydroxy-2-propoxymethyl)purines | |
| JPH05230087A (ja) | （２Ｒ）−２−〔ジ（２−プロピル）ホスホニルメトキシ〕−３−ｐ−トルエンスルホニロキシ−１−トリメチルアセトキシプロパン、その製造及び利用 | |
| US3300478A (en) | Arabinofuranosyl 2', 5'-and 3'-5'-dinucleoside phosphates and process therefor | |
| US4845084A (en) | Phosphate derivatives of substituted butyl guanines, antiviral compositions containing them, and methods of treating viral infections with them | |
| JPS58177999A (ja) | 新規アゾ−ルジヌクレオチド化合物およびその製造方法 | |
| US3338882A (en) | 2'-and 3'-phosphates of 1-beta-d-arabinofuranosylcytosine | |
| JPH05105696A (ja) | ジデオキシヌクレオシド及びホスホノホルミツク酸の複合体 | |
| NO880606L (no) | Nukleotidanaloger og fremgangsmaate for deres fremstilling. | |
| Lazrek et al. | Synthesis of the nucleotide analogue:(R, S)-9-[1-(2-hydroxyethylthio)-2-phosphonylethyl] adenine | |
| US2815342A (en) | Synthesis of pyrimidine nucleoside phosphates | |
| CA1257256A (en) | Antiviral agents | |
| Taylor et al. | D-glycero-Tetrulose 1, 4-Diphosphate (D-Erythrulose 1, 4-Diphosphate) | |
| JPH02188A (ja) | ヌクレオチド類縁体およびその製造法，ならびに抗ウイルス剤 | |
| JPH03218392A (ja) | オキセタノシン類のリン酸エステル、その用途およびその製造法 | |
| CS264223B1 (cs) | Způsob výroby N-(2-fosfonylmethoxyethyl)derivátů heterocykiických bází |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S201 | Request for registration of exclusive licence |
Free format text: JAPANESE INTERMEDIATE CODE: R314201 |
|
| S202 | Request for registration of non-exclusive licence |
Free format text: JAPANESE INTERMEDIATE CODE: R315201 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| EXPY | Cancellation because of completion of term |